cyt003-qbg10
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00574704)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cyt003-allqbg10
- cyt003-qbg10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02087644 | Phase 2 | May 1, 2014 | Cytos Biotechnology AG, University of South Florida |
| NCT01673672 | Phase 2 | Nov 1, 2012 | Creighton University, Cytos Biotechnology AG |
| NCT00890734 | Phase 2 | Apr 1, 2009 | Cytos Biotechnology AG |
| NCT00800332 | Phase 2 | Nov 1, 2008 | Cytos Biotechnology AG |
| NCT00575003 | Phase 2 | Dec 1, 2007 | Cytos Biotechnology AG, Vilnius University |
| NCT00574223 | Phase 2 | Nov 1, 2007 | Cytos Biotechnology AG |
| NCT00574704 | Phase 2 | Sep 1, 2006 | Cytos Biotechnology AG |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytos Biotechnology AG | For profit | 7 | 7 | 1 | 2006 |
| Creighton University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Vilnius University | Academic/Hospital | 1 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1